{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:34:40Z","timestamp":1790670880199,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006556","name":"Centre Hospitalier Universitaire de Toulouse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006556","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jmoldx.2020.11.002","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T12:49:40Z","timestamp":1606222180000},"page":"131-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Minimal Residual Disease Monitoring Using a 3\u2032ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma"],"prefix":"10.1016","volume":"23","author":[{"given":"Cathy","family":"Quelen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Grand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4749-8021","authenticated-orcid":false,"given":"Emeline","family":"Sarot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Brugi\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sibon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pradines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5375-7512","authenticated-orcid":false,"given":"Camille","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Brousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1123-7658","authenticated-orcid":false,"given":"Laurence","family":"Lamant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2020.11.002_bib1","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2008.18.1487","article-title":"Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group","volume":"27","author":"Brugieres","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib2","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1200\/JCO.2011.36.5411","article-title":"Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study","volume":"29","author":"Lamant","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib3","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","article-title":"Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials","volume":"30","author":"Sibon","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2141.2009.07754.x","article-title":"Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation","volume":"146","author":"Damm-Welk","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib5","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood.V93.9.3088.409k30_3088_3095","article-title":"A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2) (q25;23) translocation","volume":"93","author":"Lamant","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib6","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood.V95.10.3204","article-title":"Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: two cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like)","volume":"95","author":"Touriol","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/gcc.10232","article-title":"Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma","volume":"37","author":"Lamant","year":"2003","journal-title":"Gene Chromosomes Cancer"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib8","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/bjh.13958","article-title":"Anaplastic large cell lymphoma","volume":"173","author":"Turner","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib9","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/leu.2016.331","article-title":"Novel ALK fusion in anaplastic large cell lymphoma involving EEF1G, a subunit of the eukaryotic elongation factor-1 complex","volume":"31","author":"Palacios","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib10","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.3324\/haematol.2018.215103","article-title":"Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib","volume":"104","author":"Graetz","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2007-02-066852","article-title":"Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma","volume":"110","author":"Damm-Welk","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib12","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/sj.leu.2403888","article-title":"Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma","volume":"19","author":"Mussolin","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2013-09-526202","article-title":"Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK\u2013positive anaplastic large-cell lymphoma","volume":"123","author":"Damm-Welk","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib14","doi-asserted-by":"crossref","first-page":"26543","DOI":"10.18632\/oncotarget.25489","article-title":"Characterization and diagnostic application of genomic NPM-ALK fusion sequences in anaplastic large-cell lymphoma","volume":"9","author":"Krumbholz","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib15","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood-2009-11-251892","article-title":"Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk","volume":"115","author":"Ait-Tahar","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/cancers10040099","article-title":"Treatment options for paediatric anaplastic large cell lymphoma (ALCL): current standard and beyond","volume":"10","author":"Prokoph","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib17","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.3324\/haematol.2019.232314","article-title":"Quantification of minimal disseminated disease by quantitative PCR and digital PCR for NPM-ALK as prognostic factor in children with anaplastic large cell lymphoma","volume":"105","author":"Damm-Welk","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib18","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib19","first-page":"S49","article-title":"Limit of blank, limit of detection and limit of quantitation","volume":"29 Suppl 1","author":"Armbruster","year":"2008","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bdq.2017.04.001","article-title":"Methods to determine limit of detection and limit of quantification in quantitative real-time PCR (qPCR)","volume":"12","author":"Forootana","year":"2017","journal-title":"Biomol Detect Quantif"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib21","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/leu.2012.205","article-title":"Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis","volume":"27","author":"Mussolin","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12185-017-2338-6","article-title":"Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma","volume":"107","author":"Iijima-Yamashita","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib23","doi-asserted-by":"crossref","first-page":"viii361","DOI":"10.1093\/annonc\/mdy286.006","article-title":"ALK positive anaplastic large cell lymphoma: molecular diagnosis and minimal residual disease monitoring","volume":"29 Suppl 8","author":"Kalinova","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib24","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib25","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41375-019-0413-0","article-title":"Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1","volume":"33","author":"Pfeifer","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib26","doi-asserted-by":"crossref","first-page":"e2876","DOI":"10.1371\/journal.pone.0002876","article-title":"Mathematical analysis of copy number variation in a DNA sample using digital PCR on a nanofluidic device","volume":"3","author":"Dube","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.14082","article-title":"Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin\/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia","volume":"174","author":"Della Starza","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib28","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jmoldx.2013.10.007","article-title":"Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR","volume":"16","author":"Jennings","year":"2014","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/ejh.13084","article-title":"Droplet digital PCR for BCR\/ABL(P210) detection of chronic myeloid leukemia: a high sensitive method of the minimal residual disease and disease progression","volume":"101","author":"Wang","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib30","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1097\/HS9.0000000000000347","article-title":"Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the European MCL Network","volume":"4","author":"Drandi","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jmoldx.2015.05.007","article-title":"Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR","volume":"17","author":"Drandi","year":"2015","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib32","doi-asserted-by":"crossref","first-page":"e58177","DOI":"10.1371\/journal.pone.0058177","article-title":"Methods for applying accurate digital PCR analysis on low copy DNA samples","volume":"8","author":"Whale","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1373\/clinchem.2014.221366","article-title":"Considerations for digital PCR as an accurate molecular diagnostic tool","volume":"61","author":"Huggett","year":"2015","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib34","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3390\/s18041271","article-title":"dPCR: a technology review","volume":"18","author":"Quan","year":"2018","journal-title":"Sensors (Basel)"},{"key":"10.1016\/j.jmoldx.2020.11.002_bib35","doi-asserted-by":"crossref","first-page":"e0153317","DOI":"10.1371\/journal.pone.0153317","article-title":"Measuring digital PCR quality: performance parameters and their optimization","volume":"11","author":"Lievens","year":"2016","journal-title":"PLoS One"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157820305584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157820305584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:15:04Z","timestamp":1761502504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157820305584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1525157820305584"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2020.11.002","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal Residual Disease Monitoring Using a 3\u2032ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2020.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}